Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R. Fitzpatrick JM, et al. Among authors: de santis m, de wit r, de reijke tm. Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010. Epub 2014 Apr 3. Eur J Cancer. 2014. PMID: 24703899 Free article.
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven RF, Debois M, Collette L; Members of the EORTC Genito-Urinary Group. Schröder FH, et al. Among authors: de reijke tm. Eur Urol. 2004 Apr;45(4):457-64. doi: 10.1016/j.eururo.2003.11.016. Eur Urol. 2004. PMID: 15041109 Clinical Trial.
Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group.
Collette L, van Andel G, Bottomley A, Oosterhof GO, Albrecht W, de Reijke TM, Fossà SD. Collette L, et al. Among authors: de reijke tm. J Clin Oncol. 2004 Oct 1;22(19):3877-85. doi: 10.1200/JCO.2004.07.089. J Clin Oncol. 2004. PMID: 15459209
Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911).
Collette L, van Poppel H, Bolla M, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, Piérart M; European Organisation for Research and Treatment of Cancer (EORTC) Radiotherapy and Genito-urinary Groups. Collette L, et al. Among authors: de reijke tm. Eur J Cancer. 2005 Nov;41(17):2662-72. doi: 10.1016/j.ejca.2005.06.024. Epub 2005 Oct 11. Eur J Cancer. 2005. PMID: 16223581 Clinical Trial.
EORTC-GU group expert opinion on metastatic renal cell cancer.
de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M. de Reijke TM, et al. Eur J Cancer. 2009 Mar;45(5):765-73. doi: 10.1016/j.ejca.2008.12.010. Epub 2009 Jan 20. Eur J Cancer. 2009. PMID: 19157861 Review.
257 results